申请人:Imperial Chemical Industries Limited
公开号:US04323575A1
公开(公告)日:1982-04-06
The invention concerns compounds of the formula:- R.sup.1.CH(OH).CH.sub.2 NH.CR.sup.2 R.sup.3.A.sup.1. NH.CO.CHR.sup.4.A.sup.2.NR.sup.5. Q I wherein R.sup.1 is 3,4-bis[(3-8C)alkanoyloxy]-phenyl, 3,5- bis [(3-8C)alkanoyloxy]phenyl, 3-[(3-8C)alkanoyloxy]methyl-4-[(3-8C)alkanoyloxy]phenyl, 4-[(3-8C)alkanoyloxy]phenyl, 2-chlorophenyl or 3,5-dichloro-4-aminophenyl; R.sup.2 and R.sup.3 are independently hydrogen or (1-4C) alkyl; A.sup.1 is (1-4C) alklylene; A.sup.2 is a direct bond or (1-4C) alkylene; R.sup.4 is hydrogen, (1-6C)alkyl, phenyl-(1-4C)alkyl or halogenophenyl-(1-4 C)alkyl; and R.sup.5 is (1-6C)alkyl; or R.sup.4 and R.sup.5 together form (2-5C) alkylene; and Q is (3-12C) alkanoyl, [(3-6C)alkoxy]carbonyl, phenylacetyl, phenoxyacetyl, benzoyl or benzyloxycarbonyl, the phenyl rings of which may optionally bear a substitutent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy and trifuloromethyl; and the pharmaceutically acceptable acid-addition salts thereof; processes for their manufacture; and pharmaceutical compositions thereof. The compounds of formula I are topical anti-inflammatory agents. A representative compound is 1-[3,4-bis (pivaloyloxy)phenyl]-2-2-[(N-phenylacetyl-proyly)amino]-1,1-dimethyl-ethy lamino}ethanol.
该发明涉及以下化合物的公式:- R.sup.1.CH(OH).CH.sub.2 NH.CR.sup.2 R.sup.3.A.sup.1. NH.CO.CHR.sup.4.A.sup.2.NR.sup.5. Q I,其中R.sup.1是3,4-双[(3-8C)癸酰氧基]-苯基,3,5-双[(3-8C)癸酰氧基]苯基,3-[(3-8C)癸酰氧基]甲基-4-[(3-8C)癸酰氧基]苯基,4-[(3-8C)癸酰氧基]苯基,2-氯苯基或3,5-二氯-4-氨基苯基;R.sup.2和R.sup.3独立地是氢或(1-4C)烷基;A.sup.1是(1-4C)烷基;A.sup.2是直链键或(1-4C)烷基;R.sup.4是氢,(1-6C)烷基,苯基-(1-4C)烷基或卤代苯基-(1-4C)烷基;而R.sup.5是(1-6C)烷基;或者R.sup.4和R.sup.5共同形成(2-5C)烷基;Q是(3-12C)癸酰基,[(3-6C)癸氧基]羰基,苯乙酰基,苯氧乙酰基,苯甲酰基或苄氧羰基,其中苯环上可能选择携带卤素,(1-4C)烷基,(1-4C)癸氧基和三氟甲基等取代基;以及其药学上可接受的酸盐;制备它们的方法;以及其药物组合物。公式I的化合物是局部抗炎剂。代表性化合物是1-[3,4-双(季戊酰氧基)苯基]-2-2-[(N-苯乙酰基-丙基)氨基]-1,1-二甲基-乙基氨基}乙醇。